Marcus Bosenberg was named the inaugural director of the Yale Center for Immuno-Oncology.
Sarah Tasian was named chief of the Section of Hematologic Malignancies within the Division of Oncology at Children’s Hospital of Philadelphia.
AccessHope and Dana-Farber Cancer Institute have entered into a partnership to extend member access to specialized cancer expertise to more people living with complex cancers across the U.S.
A study led by researchers at NYU Langone Health and Perlmutter Cancer Center shows that Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to get them than non-Black men.
Researchers at City of Hope have identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer.
The ABAT enzyme helps medulloblastoma cells feed, according to a study led by USC Brain Tumor Center and Norris Comprehensive Cancer Center.
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) was approved by FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.
The European Commission has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.
The European Commission has approved Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10).
The European Commission has approved the PD-1 inhibitor Libtayo (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer whose tumor cells have ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations.
